A single-arm, open-label study conducted across 11 institutions in the United states and Canada and 15 centers in Southeast Asia demonstrated the synergistic anti-tumor activity achieved through a combination of anti-HER-2 agents with anti-PD-1 checkpoint blockade (pembrolizumab) in HER-2 positive patients (Catenacci, et al. 2020). Here, ERBB2 is linked to neoplasm.